PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 140 filers reported holding PUMA BIOTECHNOLOGY INC in Q1 2017. The put-call ratio across all filers is 1.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $582,000 | -27.5% | 54,053 | -14.4% | 0.12% | -30.8% |
| Q2 2019 | $803,000 | -38.0% | 63,142 | +89.2% | 0.17% | -93.9% |
| Q1 2019 | $1,295,000 | +142.5% | 33,378 | +27.1% | 2.76% | +2927.5% |
| Q4 2018 | $534,000 | -18.1% | 26,259 | +84.6% | 0.09% | +35.8% |
| Q3 2018 | $652,000 | -16.8% | 14,227 | +7.4% | 0.07% | -90.3% |
| Q2 2018 | $784,000 | +26.2% | 13,252 | +45.2% | 0.69% | +28.6% |
| Q1 2018 | $621,000 | -35.0% | 9,129 | -5.5% | 0.54% | -55.0% |
| Q4 2017 | $955,000 | +92.2% | 9,661 | +133.0% | 1.20% | +1688.1% |
| Q3 2017 | $497,000 | +51.1% | 4,147 | +10.1% | 0.07% | +36.7% |
| Q2 2017 | $329,000 | +8.6% | 3,767 | -53.8% | 0.05% | -9.3% |
| Q1 2017 | $303,000 | +34.1% | 8,147 | +10.6% | 0.05% | -20.6% |
| Q4 2016 | $226,000 | -56.0% | 7,366 | -3.9% | 0.07% | -72.7% |
| Q3 2016 | $514,000 | +125.4% | 7,666 | 0.0% | 0.25% | +47.3% |
| Q2 2016 | $228,000 | +132.7% | 7,666 | +130.8% | 0.17% | +25.2% |
| Q1 2016 | $98,000 | – | 3,321 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 1,417,000 | $18,010,000 | 2.24% |
| Palo Alto Investors LP | 1,405,680 | $17,866,000 | 0.87% |
| PFM Health Sciences, LP | 2,838,376 | $36,076,000 | 0.68% |
| TANG CAPITAL MANAGEMENT LLC | 349,400 | $4,441,000 | 0.60% |
| Capital Impact Advisors, LLC | 127,029 | $1,615,000 | 0.59% |
| Leap Investments LP | 29,100 | $370,000 | 0.50% |
| Spark Investment Management LLC | 454,300 | $5,774,000 | 0.40% |
| Partner Investment Management, L.P. | 27,567 | $350,000 | 0.37% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 262,945 | $3,342,000 | 0.26% |
| Rock Springs Capital Management LP | 534,400 | $6,792,000 | 0.25% |